A novel gene therapy platform for treating abnormal inflammation through immune regulation is being developed by the company. It is utilizing interleukin-10 (IL-10), a powerful cytokine that acts as a primary controller for various inflammatory processes, to target the underlying cause of inflammation and subsequently reestablish the immune system's balance. Xalud's primary product candidate, XT-150, is a locally administered plasmid DNA gene therapy that expresses IL-10 to tackle abnormal inflammation and alleviate discomfort.